文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脑胶质瘤治疗后影像学表现:进展、假性进展、假性缓解、放射性坏死。

Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

机构信息

Department of Radiology, Weill Cornell Medical Center, 525 East 68th Street, Box 141, New York, NY 10065, USA.

Department of Radiology, Weill Cornell Medical Center, 525 East 68th Street, Box 141, New York, NY 10065, USA.

出版信息

Neuroimaging Clin N Am. 2021 Feb;31(1):103-120. doi: 10.1016/j.nic.2020.09.010.


DOI:10.1016/j.nic.2020.09.010
PMID:33220823
Abstract

Radiographic monitoring of posttreatment glioblastoma is important for clinical trials and determining next steps in management. Evaluation for tumor progression is confounded by the presence of treatment-related radiographic changes, making a definitive determination less straight-forward. The purpose of this article was to describe imaging tools available for assessing treatment response in glioblastoma, as well as to highlight the definitions, pathophysiology, and imaging features typical of true progression, pseudoprogression, pseudoresponse, and radiation necrosis.

摘要

术后胶质母细胞瘤的放射影像学监测对于临床试验和确定治疗管理的下一步非常重要。由于存在与治疗相关的放射影像学改变,肿瘤进展的评估变得更加复杂,因此明确的诊断变得不那么直接。本文的目的是描述评估胶质母细胞瘤治疗反应的可用影像学工具,并强调真正进展、假性进展、假性缓解和放射性坏死的定义、病理生理学和影像学特征。

相似文献

[1]
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

Neuroimaging Clin N Am. 2021-2

[2]
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

Radiol Clin North Am. 2019-11

[3]
Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Clin Transl Oncol. 2017-12-7

[4]
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

J Neurooncol. 2017-4-5

[5]
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Neurotherapeutics. 2017-4

[6]
Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis.

Clin Nucl Med. 2005-3

[7]
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].

Wien Med Wochenschr. 2011-1

[8]
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.

J Neurooncol. 2022-6

[9]
Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Contrast Media Mol Imaging. 2018-12-2

[10]
State of the Art Treatment and Surveillance Imaging of Glioblastomas.

Semin Roentgenol. 2018-1

引用本文的文献

[1]
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

Cancer. 2025-8-15

[2]
Detecting pseudo versus true progression of glioblastoma via accurate quantitative DCE-MRI using point-of-care portable perfusion phantoms: a pilot study.

Quant Imaging Med Surg. 2025-5-1

[3]
An effective MRI perfusion threshold based workflow to triage additional F-FET PET in posttreatment high grade glioma.

Sci Rep. 2025-3-5

[4]
Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAF glioblastoma results in sustained response: A case report.

Neurooncol Adv. 2024-7-2

[5]
Resolving spatial response heterogeneity in glioblastoma.

Eur J Nucl Med Mol Imaging. 2024-10

[6]
Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma.

Am J Cancer Res. 2023-12-15

[7]
Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.

Curr Neurol Neurosci Rep. 2024-2

[8]
Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.

Medicine (Baltimore). 2023-12-22

[9]
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study.

Cancers (Basel). 2023-10-14

[10]
The value of arterial spin labelling (ASL) perfusion MRI in the assessment of post-treatment progression in adult glioma: A systematic review and meta-analysis.

Neurooncol Adv. 2023-9-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索